The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform
E Vrandecic - One of the best experts on this subject based on the ideXlab platform.
-
porcine stentless mitral Heart Valve Substitute short term clinical data
Journal of Cardiovascular Surgery, 1994Co-Authors: M Vrandecic, B Gontijo, Fernando Antonio Fantini, O C Oliveira, I C Martins, M H Oliveira, S O Avelar, E VrandecicAbstract:Beginning March 1992 to February 1994, 65 patients were submitted to mitral Valve replacement using the porcine mitral stentless Heart Valve. This group took in 65 patients, their age ranged from four to 65 with a mean of 26 years. Forty patients were below years of age. The major indication was rheumatic Heart disease sequelae in 50 patients, mitral Valve endocarditis in six, myomatous degeneration in four and in five previous mitral prosthetic Valve was replaced due to tissue failure. The preoperative functional class revealed 35 patients in class III and 30 in class IV. The longest follow-up was 23 months with a mean of 12. The surgical technique used rendered consistent and reproducible results. There was a hospital mortality of two patients or 3.1%. The hospital morbidity revealed full recovery of all patients. There were three patients reoperated because of Valve endocarditis in two and in one due to partial dehiscence of the suture at the annular level. All three patients had full recovery after a reoperation. There was a late mortality of two patients, non Valve related. The follow-up of these patients revealed full competent stentless mitral Valve in 50 patients and in nine minor to mild jets were encountered by color echo-Doppler. Most patients are in functional class I and II. The stenless concept has prove to be outstanding in the mitral position throughout the current follow-up of close to 2 years.(ABSTRACT TRUNCATED AT 250 WORDS)
-
porcine stentless aortic Heart Valve Substitute mid term clinical follow up
Journal of Cardiovascular Surgery, 1994Co-Authors: M Vrandecic, B Gontijo, Fernando Antonio Fantini, O C Oliveira, I C Martins, M H Oliveira, S O Avelar, E VrandecicAbstract:From May 1990 to January 1994, 120 patients underwent aortic Valve replacement with the use of the Biocor porcine aortic stentless Heart Valve (BPASHV). There were 83 male and 3 female patients. The age ranged from 11 seventy-six (76) years with a mean of 36. Eighty-five patients were under 40 years of age. Sixty-four patients underwent their first aortic Valve replacement due to rheumatic Heart disease, 30 because of prosthetic Valve failure and of those: 20 were due to primary tissue failure and in 10 due to prosthetic endocarditis, native aortic bicuspid Valve in 11 and senile calcificant aortic Valve disease in four. Thirty-three patients had aortic annular related pathology. Their preoperative functional class revealed 61 patients in class III and 59 in class IV. The longest follow-up in this aortic group was 42 months with a mean of 26. The surgical technique used rendered consistent and reproducible results. There was a hospital mortality of six patients (5%). The mortality was not Valve related. The hospital morbidity in 14 revealed full recovery of all patients. There were four late reoperations, in two due to recurrent endocarditis and in the last two because of paravalvar leak. There was a late mortality of four patients (non Valve related). The follow-up of these patients revealed full competent aortic stentless Valve in 97 patients and only minor jet in nine. Most patients are in functional class I and II. The Aortic stentless concept has proven to be outstanding with the use of the Biocor Aortic stentless Valve throughout the current follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
Jorg S Sachweh - One of the best experts on this subject based on the ideXlab platform.
-
introduction of a flexible polymeric Heart Valve prosthesis with special design for aortic position
European Journal of Cardio-Thoracic Surgery, 2004Co-Authors: Sabine Daebritz, Bernd Fausten, Benita Hermanns, Joerg Schroeder, J Groetzner, R Autschbach, B J Messmer, Jorg S SachwehAbstract:Objective: Current prosthetic Heart Valves necessitate permanent anticoagulation or have limited durability and impaired hemodynamic performance compared to natural Valves. Recently a polymeric Valve prostheses with special design for mitral position demonstrated excellent in vitro and in vivo results with improved durability and no need for permanent anticoagulation. In this study, a respective flexible polymeric aortic Valve is presented and in vitro and in vivo results are reported. Methods: The aortic prosthesis (ADIAM® lifescience AG, Erkelenz, Germany) is entirely made of polycarbonaturethane. The tri-leaflet flexible prosthesis mimicks the natural aortic Valve and has a diminished pressure loss and reduced stress and strain peaks at the commissures. The Valve underwent long-term in vitro testing and in vivo-testing in a growing calve animal model (20 weeks, 7 aortic Valves) and was compared to two different commercial bioprostheses. Results: The polymeric aortic Heart Valve Substitute demonstrated excellent in vitro and in vivo hemodynamics. Five/seven animals with aortic PCU-prostheses had an excellent clinical long-term course. The explanted Valves showed a variable degree of calcification. Two of the seven animals died at 27 and 77 days due to pannus overgrowth causing severe LVOTO without degeneration of the Valve itself. Both animals with commercial bioprostheses had to be sacrificed because of congestive Heart failure related to structural degeneration of the bioprosthesis after 10 and 30 days of implantation. There was no increased thrombogenity of the PCU Valves compared to bioprostheses. Conclusion: The new flexible polymeric aortic Valve prosthesis is superior to current bioprostheses in animal testing.
M Vrandecic - One of the best experts on this subject based on the ideXlab platform.
-
porcine stentless mitral Heart Valve Substitute short term clinical data
Journal of Cardiovascular Surgery, 1994Co-Authors: M Vrandecic, B Gontijo, Fernando Antonio Fantini, O C Oliveira, I C Martins, M H Oliveira, S O Avelar, E VrandecicAbstract:Beginning March 1992 to February 1994, 65 patients were submitted to mitral Valve replacement using the porcine mitral stentless Heart Valve. This group took in 65 patients, their age ranged from four to 65 with a mean of 26 years. Forty patients were below years of age. The major indication was rheumatic Heart disease sequelae in 50 patients, mitral Valve endocarditis in six, myomatous degeneration in four and in five previous mitral prosthetic Valve was replaced due to tissue failure. The preoperative functional class revealed 35 patients in class III and 30 in class IV. The longest follow-up was 23 months with a mean of 12. The surgical technique used rendered consistent and reproducible results. There was a hospital mortality of two patients or 3.1%. The hospital morbidity revealed full recovery of all patients. There were three patients reoperated because of Valve endocarditis in two and in one due to partial dehiscence of the suture at the annular level. All three patients had full recovery after a reoperation. There was a late mortality of two patients, non Valve related. The follow-up of these patients revealed full competent stentless mitral Valve in 50 patients and in nine minor to mild jets were encountered by color echo-Doppler. Most patients are in functional class I and II. The stenless concept has prove to be outstanding in the mitral position throughout the current follow-up of close to 2 years.(ABSTRACT TRUNCATED AT 250 WORDS)
-
porcine stentless aortic Heart Valve Substitute mid term clinical follow up
Journal of Cardiovascular Surgery, 1994Co-Authors: M Vrandecic, B Gontijo, Fernando Antonio Fantini, O C Oliveira, I C Martins, M H Oliveira, S O Avelar, E VrandecicAbstract:From May 1990 to January 1994, 120 patients underwent aortic Valve replacement with the use of the Biocor porcine aortic stentless Heart Valve (BPASHV). There were 83 male and 3 female patients. The age ranged from 11 seventy-six (76) years with a mean of 36. Eighty-five patients were under 40 years of age. Sixty-four patients underwent their first aortic Valve replacement due to rheumatic Heart disease, 30 because of prosthetic Valve failure and of those: 20 were due to primary tissue failure and in 10 due to prosthetic endocarditis, native aortic bicuspid Valve in 11 and senile calcificant aortic Valve disease in four. Thirty-three patients had aortic annular related pathology. Their preoperative functional class revealed 61 patients in class III and 59 in class IV. The longest follow-up in this aortic group was 42 months with a mean of 26. The surgical technique used rendered consistent and reproducible results. There was a hospital mortality of six patients (5%). The mortality was not Valve related. The hospital morbidity in 14 revealed full recovery of all patients. There were four late reoperations, in two due to recurrent endocarditis and in the last two because of paravalvar leak. There was a late mortality of four patients (non Valve related). The follow-up of these patients revealed full competent aortic stentless Valve in 97 patients and only minor jet in nine. Most patients are in functional class I and II. The Aortic stentless concept has proven to be outstanding with the use of the Biocor Aortic stentless Valve throughout the current follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
John E Mayer - One of the best experts on this subject based on the ideXlab platform.
-
application of tissue engineering principles toward the development of a semilunar Heart Valve Substitute
Tissue Engineering, 2004Co-Authors: Christopher K Breuer, Bret A Mettler, Tiffany Anthony, Virna L Sales, Frederick J Schoen, John E MayerAbstract:Heart Valve disease is a significant medical problem worldwide. Current treatment for Heart Valve disease is Heart Valve replacement. State of the art replacement Heart Valves are less than ideal and are associated with significant complications. Using the basic principles of tissue engineering, promising alternatives to current replacement Heart Valves are being developed. Significant progress has been made in the development of a tissue-engineered semilunar Heart Valve Substitute. Advancements include the development of different potential cell sources and cell-seeding techniques; advancements in matrix and scaffold development and in polymer chemistry fabrication; and the development of a variety of bioreactors, which are biomimetic devices used to modulate the development of tissue-engineered neotissue in vitro through the application of biochemical and biomechanical stimuli. This review addresses the need for a tissue-engineered alternative to the current Heart Valve replacement options. The basics o...
Sabine Daebritz - One of the best experts on this subject based on the ideXlab platform.
-
introduction of a flexible polymeric Heart Valve prosthesis with special design for aortic position
European Journal of Cardio-Thoracic Surgery, 2004Co-Authors: Sabine Daebritz, Bernd Fausten, Benita Hermanns, Joerg Schroeder, J Groetzner, R Autschbach, B J Messmer, Jorg S SachwehAbstract:Objective: Current prosthetic Heart Valves necessitate permanent anticoagulation or have limited durability and impaired hemodynamic performance compared to natural Valves. Recently a polymeric Valve prostheses with special design for mitral position demonstrated excellent in vitro and in vivo results with improved durability and no need for permanent anticoagulation. In this study, a respective flexible polymeric aortic Valve is presented and in vitro and in vivo results are reported. Methods: The aortic prosthesis (ADIAM® lifescience AG, Erkelenz, Germany) is entirely made of polycarbonaturethane. The tri-leaflet flexible prosthesis mimicks the natural aortic Valve and has a diminished pressure loss and reduced stress and strain peaks at the commissures. The Valve underwent long-term in vitro testing and in vivo-testing in a growing calve animal model (20 weeks, 7 aortic Valves) and was compared to two different commercial bioprostheses. Results: The polymeric aortic Heart Valve Substitute demonstrated excellent in vitro and in vivo hemodynamics. Five/seven animals with aortic PCU-prostheses had an excellent clinical long-term course. The explanted Valves showed a variable degree of calcification. Two of the seven animals died at 27 and 77 days due to pannus overgrowth causing severe LVOTO without degeneration of the Valve itself. Both animals with commercial bioprostheses had to be sacrificed because of congestive Heart failure related to structural degeneration of the bioprosthesis after 10 and 30 days of implantation. There was no increased thrombogenity of the PCU Valves compared to bioprostheses. Conclusion: The new flexible polymeric aortic Valve prosthesis is superior to current bioprostheses in animal testing.
